AMGEN INC
No enriched coverage for $AMGN in the last 7 days.
No SEC Form 4 filings for $AMGN in the last 30 days.
The article is primarily promotional and does not provide verifiable news about Amgen. It claims Amgen’s CFO Peter Griffith is retiring, but offers no sourcing or details. It also discusses generative AI and humanoid-robot forecasts by Amazon CEO Andy Jassy and Elon Musk, and promotes newsletter subscriptions and stock-picking claims.
Amgen (NASDAQ:AMGN) said on May 19 that CFO Peter Griffith, Executive Vice President since 2020, will retire. Thomas Dittrich will succeed him, returning to Amgen July 1 as EVP and taking over as CFO on Sept. 1, with Griffith staying through January 2027 to support the transition.
Amgen's CFO Peter Griffith is retiring, with Thomas Dittrich rejoining as the new CFO on September 1, 2026. Simultaneously, shareholders rejected a proposal for an independent board chair, highlighting a focus on leadership continuity versus oversight. These changes are analyzed for their potential influence on Amgen's investment narrative, especially concerning its diversified drug portfolio, R&D spend, and competitive pressures.
